Claims for Patent: 9,452,165

Summary for Patent: 9,452,165

Title:	Small molecule TRAIL gene induction by normal and tumor cells as an anticancer therapy
Abstract:	Methods and compositions relating to TIC10 are described according to aspects of the present invention. The compositions and methods have utility in treating disease, particularly cancer in a subject in need thereof, including a human subject as well as subjects of other species. The compositions have utility in treating brain cancer in a subject in need thereof.
Inventor(s):	El-Deiry; Wafik S. (Bryn Mawr, PA), Allen; Joshua E. (Hershey, PA), Wu; Gen Sheng (Troy, MI)
Assignee:	THE PENN STATE RESEARCH FOUNDATION (University Park, PA)
Application Number:	14/733,740
Patent Claims:	1. A method of treating a subject having cancer, comprising: administering to the subject a pharmaceutical composition comprising a pharmaceutically effective amount of: ##STR00011## or a pharmaceutically acceptable salt, hydrate, and/or solvate thereof, wherein the cancer is adenocarcinoma. 2. The method of claim 1, wherein the subject has a pre-neoplastic hyperproliferation, a cancer in-situ, a neoplasm or a metastasis. 3. The method of claim 1, wherein the cancer is a metastatic cancer. 4. The method of claim 1, wherein the cancer is a grade IV cancer. 5. The method of claim 1, wherein the cancer is a late stage cancer. 6. The method of claim 1, wherein the cancer harbors an oncogenic alteration. 7. The method of claim 6, wherein the oncogenic alteration is inactivation of a tumor suppressor. 8. The method of claim 7, wherein p53 is inactivated. 9. The method of claim 7, wherein PTEN is inactivated. 10. The method of claim 6, wherein the oncogenic alteration is activation of an oncogene. 11. The method of claim 10, wherein EGFR, Her2, and/or KRAS is mutated. 12. The method of claim 1, further comprising administering a second therapeutic to the subject, wherein the second therapeutic comprises an anti-cancer agent. 13. The method of claim 12, wherein the anti-cancer agent is a mitotic inhibitor. 14. The method of claim 12, wherein the anti-cancer agent is selected from the group consisting of paclitaxel, docetaxel, and a combination thereof. 15. The method of claim 1, further comprising administering a second therapeutic to the subject, wherein the second therapeutic comprises an anti-angiogenic agent. 16. The method of claim 15, wherein the anti-angiogenic agent is bevacizumab. 17. The method of claim 1, wherein the pharmaceutical composition is administered orally. 18. The method of claim 1, wherein the pharmaceutical composition is administered via a route of administration selected from the group consisting of rectal, nasal, pulmonary, epidural, ocular, otic, intraarterial, intracardiac, intracerebroventricular, intradermal, intravenous, intramuscular, intraperitoneal, intraosseous, intrathecal, intravesical, subcutaneous, topical, transdermal, transmucosal, sublingual, buccal, vaginal, and inhalational routes of administration. 19. The method of claim 1, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier. 20. The method of claim 1, wherein the pharmaceutical composition is a solid dosage form. 21. The method of claim 1, wherein the pharmaceutical composition is a liquid dosage form. 22. The method of claim 21, wherein the liquid dosage form is an injectable liquid.

Details for Patent 9,452,165

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2039-02-26